Related Experiment Videos
Acarboxyprothrombin concentration [corrected] after oral prophylactic vitamin K
R von Kries1, S Kreppel, A Becker
1Department of Paediatrics, University of Düsseldorf, Federal Republic of Germany.
Archives of Disease in Childhood
|September 1, 1987
Summary
Oral vitamin K prophylaxis significantly reduces acarboxyprothrombin (PIVKA II) detection in newborns. This preventative measure ensures adequate factor II clotting concentration, preventing hemorrhagic disease of the newborn.
Area of Science:
- Neonatal Medicine
- Pediatric Hematology
- Nutritional Biochemistry
Background:
- Hemorrhagic disease of the newborn (HDN) is a serious condition.
- Vitamin K deficiency is a primary cause of HDN.
- Early detection of vitamin K deficiency markers is crucial.
Purpose of the Study:
- To evaluate the efficacy of oral vitamin K1 prophylaxis.
- To assess the impact on acarboxyprothrombin (PIVKA II) levels.
- To determine the effect on factor II clotting concentration in neonates.
Main Methods:
- Administered 1 mg of oral vitamin K1 with the first feed.
- Monitored PIVKA II detection rates on day 5.
- Measured factor II clotting concentration in infants.
Main Results:
- Oral vitamin K prophylaxis reduced PIVKA II detection from 48% to 0% by day 5.
- No infants receiving prophylaxis had factor II clotting below 40%.
- 34 of 95 infants without prophylaxis had factor II clotting below 40%.
Conclusions:
- Oral vitamin K1 prophylaxis is highly effective in preventing vitamin K deficiency in newborns.
- This prophylaxis strategy significantly reduces the risk of both classical and late-onset HDN.
- Routine oral vitamin K administration is recommended for neonatal care.